15/07/2026 FDA granted priority review to Roche’s Gazyva for adults with primary membranous nephropathy InnoCare reported Phase 3 results for soficitinib in atopic dermatitis FDA granted priority review to Roche’s Gazyva for adults with primary membranous nephropathy (Ref) Roche announced that the US FDA had granted priority review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab; anti-CD20) for the treatment of primary me

(Focus - Singapore) Atopic Dermatitis (AD) can have a profound impact on individuals' quality of life, causing persistent itching,...